



Firzan Nainu <firzannainu@unhas.ac.id>

Reviewer Invitation for LFS-D-22-03849

1 message

Feng Gao <em@editorialmanager.com>
Reply-To: Feng Gao <fgao@fmmu.edu.cn>
To: Firzan Nainu <firzannainu@unhas.ac.id>

Wed, Nov 2, 2022 at 9:01 AM

Ms. Ref. No.: LFS-D-22-03849
Title: Ozone attenuates chemotherapy-induced peripheral neuropathy via upregulating AMPK-SOCS3 axis
Corresponding Author: professor Wentao Liu
Life Sciences

Dear Dr. Nainu,

I would be grateful if you would review a manuscript entitled "Ozone attenuates chemotherapy-induced peripheral neuropathy via upregulating AMPK-SOCS3 axis" submitted for potential publication in Life Sciences. The Abstract is appended below.

You should treat this invitation, the manuscript and your review (as well as other reviewer comments shared with you) as confidential. You must not share your review or information about the review process with anyone without the agreement of the editors and authors involved, irrespective of the publication outcome. If the manuscript is rejected by this journal and the author agrees that the submission be transferred to another Elsevier journal via the Article Transfer Service, we may securely transfer your reviewer comments and name/contact details to the receiving journal editor for their peer review purposes.

We kindly ask that you respond to this invitation within %INVITE_RESPONSE_DAYS days of receipt of this email. Should you decide to review this manuscript, you will be asked to submit your review within 14 days of accepting this invitation. We value your time commitment to the journal. Please do not accept this invitation if you feel that you cannot commit to the deadline.

If you are willing to review this manuscript, please click on the link below. (At this time, EM does not support accepting or declining this invitation using your mobile browser.)

<https://www.editorialmanager.com/lfs/l.asp?i=1446726&l=MUMJ2DZ2>

If you are unable, please click on the link below. We would appreciate receiving suggestions for alternative reviewers:

<https://www.editorialmanager.com/lfs/l.asp?i=1446727&l=GWEPFM4X>

Alternatively, you may register your response by accessing the Editorial Manager for Life Sciences as a REVIEWER using the login credentials below:

<https://www.editorialmanager.com/lfs/>

Your username is: FNainu-759

If you do not know your confidential password, you may reset it by clicking this link: <https://www.editorialmanager.com/lfs/l.asp?i=1446728&l=3JVEA8Q2>

The manuscript reference is LFS-D-22-03849.

As a reviewer you are entitled to use our Open Access content. Read more about Open Access here:

<http://www.elsevier.com/openaccess>

You have been pre-registered as a reviewer. You are welcome to edit your reviewer profile using the Change Details tab found on the upper left menu.

Upon submission of your review report to the system, you will get access to your personalized Elsevier reviews profile page as well as the possibility of creating a public page listing your reviews across all publishers in just a few steps! See <http://www.reviewerrecognition.elsevier.com> and <http://www.reviewerpage.com> for more information.

As a reviewer you are entitled to complimentary access to references, abstracts, and full-text articles on ScienceDirect and Scopus for 30 days. Full details on how to claim your access via Reviewer Hub (reviewerhub.elsevier.com) will be provided upon your acceptance of this invitation to review.

Please visit the Elsevier Reviewer Hub (reviewerhub.elsevier.com) to manage all your refereeing activities for this and other Elsevier journals on Editorial Manager.

Sincerely,
Feng Gao, MD, PhD
Editor
Life Sciences

Reviewer Guidelines are now available to help you with your review: <http://www.elsevier.com/wps/find/reviewershome.reviewers/reviewersguidelines>

ABSTRACT:

Background : Chemotherapy-induced peripheral neuropathy (CIPN) is a common severe adverse reaction of chemotherapeutics, seriously affecting the outcome of chemotherapy and patients' quality of life. However, effective medication is lacking. Our previous study found ozone could alleviate neuropathic pain. DAMPs/TLR4/Tissue factor (TF)-mediated neuroinflammation and microcirculation disturbance is the main reason of CIPN. Suppressors of cytokine signaling (SOCS) 3 is an endogenous negative feedback regulator of inflammation via inhibiting TLR4.

Methods: Oxaliplatin (L-OHP) was used to establishing mice CIPN model. The nociception was assessed by measuring the incidence of foot withdrawal in response to mechanical indentation in mice. Cell signaling was assayed using western blotting, and immunohistochemistry. The mouse leukemia cells of monocyte macrophage line RAW264.7 were cultured to investigate the effects of ozone on macrophage.

Results: Ozone decreased the expression of TF in the blood and sciatic nerve. Ozone upregulated AMPK-SOCS3 axis to relief CIPN and inhibit TF expression in vivo. Ozone induced SOCS3 expression to inhibit p38/TF signaling in Raw 246.7 cells. Ozone prevented L-OHP-induced sciatic nerve demyelination. Ozone inhibited microglia activation and decreased c-Fos and CGRP expression in the spinal dorsal horn.

Conclusions: In this study, we demonstrated that ozone could alleviate CIPN via upregulating AMPK-SOCS3 axis to inhibit TF expression, and provided a potential treatment for CIPN.

Please note: Reviews are subject to a confidentiality policy,
http://service.elsevier.com/app/answers/detail/a_id/14156/supporthub/publishing/

#REV_LFS#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/lfs/login.asp?a=r>). Please contact the publication office if you have any questions.



Life Sciences

Certificate of Reviewing

Awarded for 1 review in November 2022
presented to

FIRZAN NAINU

in recognition of the review contributed to the journal

The Editors of Life Sciences

